1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

Gilead's HIV franchise looks secure as 'son of Viread' impresses in PhIII

 
• By Sukaina Virji

Two Phase III trials of Gilead Sciences' once-daily tablet containing its next-generation Viread product, tenofovir alafenamide (TAF), have met their primary objectives. The data are expected to help Gilead fight off generic competition to its hugely successful HIV franchise.

Two Phase III trials of Gilead Sciences' once-daily tablet containing its next-generation Viread product, tenofovir alafenamide (TAF), have met their primary objectives. The data are expected to help Gilead fight off generic competition to its hugely successful HIV franchise.

The latest data demonstrated that the single-tablet regimen comprising elvitegravir 150mg, cobicistat 150mg, emtricitabine 200mg and TAF 10mg (E/C/F/TAF), was non-inferior to Gilead's Stribild (elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir disoproxil fumarate [Viread] 300mg) based on the proportion of patients with HIV RNA levels (viral load) of less than 50

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapy Areas

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

 
• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.